Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The future: screening and effective intervention

S A Brunton1

  • 1Department of Family Medicine, Long Beach Memorial Medical Center, California 90806, USA.

The American Journal of Medicine
|July 31, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis.

Journal of internal medicine·2021
Same author

The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.

International journal of clinical practice·2015
Same author

Dust mites and asthma.

Hospital practice (1995)·2000
Same author

Randomized clinical trial of a diagnostic instrument for pain complaints.

Family medicine·1999
Same author

Lifestyle modification: weight control, exercise, and smoking cessation.

The American journal of medicine·1996
Same author

Gag clauses in managed care.

Hospital practice (1995)·1996
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Effective cardiovascular disease prevention combines lifestyle changes with lipid-lowering therapy, particularly 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. These therapies significantly reduce cardiovascular risk and improve endothelial function.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) prevention remains challenging despite increased risk factor understanding and new interventions.
  • Community-based programs show modest long-term benefits, especially for high-risk groups.
  • Lipid-lowering therapy is crucial alongside diet and lifestyle changes.

Purpose of the Study:

  • To evaluate the effectiveness of current strategies in large-scale cardiovascular disease prevention.
  • To highlight the role of specific pharmacotherapies in managing cardiovascular risk.
  • To assess the utility of HMG-CoA reductase inhibitors in primary and secondary prevention.

Main Methods:

  • Review of recent studies on community-based prevention programs.

Related Experiment Videos

  • Analysis of data on lipid-lowering therapy, focusing on HMG-CoA reductase inhibitors.
  • Evaluation of drug effects on endothelial function and coronary perfusion.

    • Main Results:

    • Large-scale educational programs yield modest long-term benefits.
    • 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are highly effective in reducing CVD risk.
    • These inhibitors improve endothelial function and coronary perfusion, supporting medical management.

    Conclusions:

    • Combining lifestyle modification with aggressive medical therapy, especially HMG-CoA reductase inhibitors, is key for effective CVD prevention.
    • HMG-CoA reductase inhibitors offer a valuable medical management option for select CVD patients.
    • Further research may refine strategies for optimal cardiovascular risk reduction.